Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-04-26 07:00:05
Complete data analysis confirms that the primary endpoint of improved clinical
response and key secondary endpoints were met in a subprotocol under the
platform ACCORD2 study where bemcentinib was added to standard of care therapy
BerGenBio to confirm the ACCORD2 data by progressing bemcentinib into EU
-SolidAct, a pan-European platform COVID-19 study enrolling up to 500 patients
Bergen, Norway,April 26, 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, announced today that a complete data analysis of a
randomized phase II study of bemcentinib in combination with standard of care
(SoC) therapy, ACCORD2 (BGBIL019), in hospitalized COVID-19 patients confirms
that the primary efficacy endpoint was met.
At the July 2021 European Congress of Clinical Microbiology & Infectious
Diseases (ECCMID) meeting, the Company previously presented preliminary data
from the ACCORD2 study in combination with a second COVID-19 study (BGBC020)
showing evidence of therapeutic benefit on meaningful clinical endpoints in a
total of 177 patients. Today's announcement is the first time complete ACCORD2
data in a total of 61 treated patients has been separately reported.
Overall, 90% of patients treated with bemcentinib + SoC (26 of 29) experienced a
clinical response by day 29 (median 7.0 days), as defined by either a two-point
improvement in World Health Organization (WHO) category from baseline score, or
discharge from hospital, whichever arose sooner. This compared to 69% (22 of 32
patients) with a clinical response to SoC treatment alone (median 9.5 days),
showing statistical significance.
The data was generated under a sub-protocol of the platform ACCORD2 study
(ACCORD2